Trade Mark Journal No.2026/037 11 September 2026
WO0000001921682 (42)
Office of origin: United States of America
Date of International Registration:26 February 2026
Date of designation in the UK:
26 February 2026
International priority date claimed: 27 August 2025
(United States of America)
(99361623)
- Class 42
- Drug discovery, pharmaceutical drug development, and drug validation services; pharmaceutical research and development; providing medical research and scientific information in the fields of pharmaceuticals, biology, chemistry, biochemistry, biotechnology, and clinical trials; providing scientific, pharmaceutical, clinical research and medical research information about pharmaceutical drug development via the internet; consulting services in the fields of pharmaceuticals, biology, chemistry, biochemistry, biotechnology research, and design, planning, and implementation of clinical trials; research and development of new products; scientific, research and development services; medical research services; providing information about medical and scientific research relating to the identification of ubiquitin ligases for the purposes of degrading a disease-causing protein; scientific consultancy services in the field of identifying ubiquitin ligases for the purposes of degrading a disease-causing protein; providing information about medical and scientific research with respect to using a photocatalyst molecule for labeling a protein proximate to a target disease-causing protein within a live cell; scientific consultancy services in the field of using a photocatalyst molecule for labeling a protein proximate to a target disease-causing protein within a live cell.
SEED Therapeutics US, Inc.
Representative: Haseltine Lake Kempner LLP, One Portwall Square, Portwall Lane Bristol BS1 6BH UNITED KINGDOM